Want to see TSE:VPT full AI Analyst Report?
VentriPoint Diagnostics (VPT) Price & Analysis
VPT Stock Chart & Stats
- Day’s Range
- CAD 0.08 - CAD 0.08
- 52-Week Range
- CAD 0.08 - CAD 0.19
- Previous Close
- CAD 0.08
- Volume
- 79.10K
- Average Volume (3M)
- 127.56K
- Market Cap
- CAD 15.43M
- Enterprise Value
- CAD 22.72M
- Total Cash (Recent Filing)
- CAD 333.63K
- Total Debt (Recent Filing)
- CAD 2.62M
- Price to Earnings (P/E)
- ―
- Beta
- -0.76
- Next Earnings
- Dec 02, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Sustained revenue expansion indicates growing adoption of the company’s cardiac imaging analytics and supports a larger commercial base. If maintained, this growth can improve operating leverage, strengthen market presence, and provide a foundation for eventual profitability.
High Gross Margin
The exceptionally high gross margin suggests the software-led offering has attractive underlying unit economics once operating costs are covered. This creates meaningful potential for incremental revenue to contribute strongly toward research, commercialization, and future earnings improvement.
Narrowing Losses
Improvement from materially worse margins in prior years indicates some progress toward financial stabilization. Continued reduction in losses could extend the company’s runway and allow its high-margin revenue model to translate into stronger operating performance over the next several quarters.
Bears Say
Persistent Unprofitability
Ongoing negative earnings show that the current revenue base does not yet cover operating costs, despite strong gross margins. Until the company reaches break-even, growth may require additional funding and management must convert commercial expansion into durable operating profitability.
Negative Cash Generation
Continued operating and free-cash-flow deficits mean the business is not self-funding and cash is still being consumed to support operations. This limits financial flexibility, increases dependence on capital access, and can constrain investment in product development or commercialization.
Deteriorated Capital Structure
Negative equity reflects accumulated losses that have more than offset contributed capital, while debt materially exceeds the stated asset base. This weak capital structure reduces resilience, limits financing flexibility, and increases reliance on external funding to sustain the business.
VentriPoint Diagnostics News
VPT FAQ
What was VentriPoint Diagnostics’s price range in the past 12 months?
What is VentriPoint Diagnostics’s market cap?
When is VentriPoint Diagnostics’s upcoming earnings report date?
How were VentriPoint Diagnostics’s earnings last quarter?
Is VentriPoint Diagnostics overvalued?
Does VentriPoint Diagnostics pay dividends?
What is VentriPoint Diagnostics’s EPS estimate?
How many shares outstanding does VentriPoint Diagnostics have?
What happened to VentriPoint Diagnostics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of VentriPoint Diagnostics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
VentriPoint Diagnostics
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Hugh MacNaught
- Employees
- 10
- Website
- www.ventripoint.com
- Address
- 18 Hook Avenue, Toronto, ON, M6P 1T4, CA
VentriPoint Diagnostics (VPT) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 13 |
| Technical Analysis | 4 | 4 | 1 |
| Moving Averages | 0 | 0 | 12 |


